{
  "resourceType": "ConceptMap",
  "id": "CPT",
  "url": "http://fhir.org/guides/nachc/hiv-cds/ConceptMap/CPT",
  "name": "CPT",
  "title": "CPT",
  "status": "draft",
  "experimental": false,
  "description": "Concept mapping from content extended codes to CPT",
  "group": [ {
    "source": "http://fhir.org/guides/nachc/hiv-cds/CodeSystem/hiv-custom",
    "target": "http://www.ama-assn.org/go/cpt",
    "element": [ {
      "code": "NACHC.B2.DE103",
      "display": "Antinuclear antibodies (ANA)",
      "target": [ {
        "code": "86038",
        "display": "Antinuclear antibodies (ANA)",
        "equivalence": "equivalent"
      } ]
    }, {
      "code": "NACHC.B2.DE104",
      "display": "Hepatitis C antibody",
      "target": [ {
        "code": "86803",
        "display": "Hepatitis C antibody",
        "equivalence": "equivalent"
      } ]
    }, {
      "code": "NACHC.B2.DE105",
      "display": "Hepatitis C antibody; confirmatory test (eg, immunoblot)",
      "target": [ {
        "code": "86804",
        "display": "Hepatitis C antibody; confirmatory test (eg, immunoblot)",
        "equivalence": "equivalent"
      } ]
    }, {
      "code": "NACHC.B2.DE106",
      "display": "Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, direct probe technique",
      "target": [ {
        "code": "87520",
        "display": "Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, direct probe technique",
        "equivalence": "equivalent"
      } ]
    }, {
      "code": "NACHC.B2.DE107",
      "display": "Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, amplified probe technique, includes reverse transcription when performed",
      "target": [ {
        "code": "87521",
        "display": "Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, amplified probe technique, includes reverse transcription when performed",
        "equivalence": "equivalent"
      } ]
    }, {
      "code": "NACHC.B2.DE108",
      "display": "Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, quantification, includes reverse transcription when performed",
      "target": [ {
        "code": "87522",
        "display": "Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, quantification, includes reverse transcription when performed",
        "equivalence": "equivalent"
      } ]
    }, {
      "code": "NACHC.B2.DE109",
      "display": "Infectious agent genotype analysis by nucleic acid (DNA or RNA); Hepatitis C virus",
      "target": [ {
        "code": "87902",
        "display": "Infectious agent genotype analysis by nucleic acid (DNA or RNA); Hepatitis C virus",
        "equivalence": "equivalent"
      } ]
    }, {
      "code": "NACHC.B2.DE113",
      "display": "RNA testing for Hepatitis C documented as performed within 6 months prior to initiation of antiviral treatment for Hepatitis C (HEP-C)",
      "target": [ {
        "code": "3218F",
        "display": "RNA testing for Hepatitis C documented as performed within 6 months prior to initiation of antiviral treatment for Hepatitis C (HEP-C)",
        "equivalence": "equivalent"
      } ]
    }, {
      "code": "NACHC.B2.DE114",
      "display": "Hepatitis C quantitative RNA testing documented as performed at 12 weeks from initiation of antiviral treatment (HEP-C)",
      "target": [ {
        "code": "3220F",
        "display": "Hepatitis C quantitative RNA testing documented as performed at 12 weeks from initiation of antiviral treatment (HEP-C)",
        "equivalence": "equivalent"
      } ]
    }, {
      "code": "NACHC.B2.DE115",
      "display": "Ribonucleic acid (RNA) testing for Hepatitis C viremia ordered or results documented (HEP C)",
      "target": [ {
        "code": "3265F",
        "display": "Ribonucleic acid (RNA) testing for Hepatitis C viremia ordered or results documented (HEP C)",
        "equivalence": "equivalent"
      } ]
    }, {
      "code": "NACHC.B2.DE116",
      "display": "Hepatitis C genotype testing documented as performed prior to initiation of antiviral treatment for Hepatitis C (HEP C)",
      "target": [ {
        "code": "3266F",
        "display": "Hepatitis C genotype testing documented as performed prior to initiation of antiviral treatment for Hepatitis C (HEP C)",
        "equivalence": "equivalent"
      } ]
    }, {
      "code": "NACHC.B2.DE117",
      "display": "Hepatitis C screening documented as performed (HIV)",
      "target": [ {
        "code": "3514F",
        "display": "Hepatitis C screening documented as performed (HIV)",
        "equivalence": "equivalent"
      } ]
    }, {
      "code": "NACHC.B2.DE118",
      "display": "Patient receiving antiviral treatment for Hepatitis C (HEP-C)",
      "target": [ {
        "code": "4150F",
        "display": "Patient receiving antiviral treatment for Hepatitis C (HEP-C)",
        "equivalence": "equivalent"
      } ]
    }, {
      "code": "NACHC.B2.DE119",
      "display": "Collection of venous blood by venipuncture",
      "target": [ {
        "code": "36415",
        "display": "Collection of venous blood by venipuncture",
        "equivalence": "equivalent"
      } ]
    }, {
      "code": "NACHC.B2.DE120",
      "display": "Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver",
      "target": [ {
        "code": "81596",
        "display": "Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver",
        "equivalence": "equivalent"
      } ]
    } ]
  } ]
}